A GENETIC RISK PROFILE IN LONGITUDINAL SYSTEMIC LUPUS ERYTHEMATOSES COHORTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 自身免疫性疾病患者的血液循环中可能存在某些蛋白质，这可能是疾病发生发展的一个重要因素。这些蛋白质可以与白细胞相互作用，这种相互作用可能会对多个组织和器官造成损害。有一些证据表明，遗传因素(基因)可能有助于自身免疫性疾病的发展。 该研究的三个目标是：1)建立多种族系统性红斑狼疮(SLE)患者的多中心共同核心数据库(Profile队列)，包括已在当地队列中的既有患者以及即将招募的新患者；2)评估1号染色体基因(Q21-32)在SLE患者这个队列中预测疾病表型[肾脏、心血管、肺和中枢神经系统(CNS)受累]的能力；以及3)建立三个家族(狼疮患者和亲生父母)和健康对照的核心集合，以确认和缩小SLE候选区域和基因的识别范围。前两个目标将通过对700名SLE患者的纵向研究来实现。第三个目标将通过对350个三人家庭(狼疮患者和两个生物患者)的研究来实现。 将有一个额外的队列(称为CASSLE)，其中将包括800名任何病程的狼疮患者，以及800名对照组。每个对照将根据种族、年龄和性别与病例相匹配。程序将与个人资料队列中的程序相同，只是参与者只有一次考察访问。 这些目标将有助于创造最多的狼疮患者，在这些患者中，精心收集的数据将可用于研究狼疮的遗传学以及遗传学(相对于其他因素)对疾病表型的相对贡献。 芝加哥队列的目标是为狼疮患者提供300名侧写/盒式患者和50个三人家庭以及200名匹配的对照。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with autoimmune disease may have certain proteins in their circulation which may be an important factor in the development of disease. These proteins can interact with white blood cells and this interaction may cause damage to multiple tissues and organs. There is some evidence that inherited factors (genes) may contribute to the development of autoimmune disease. The three aims of the research study are: 1) Establish a multi-center common core database of systemic lupus erythematosus (SLE) patients from multiple ethnicities (profile cohorts) comprised of established patients who are already in local cohorts as well as new patients to be recruited; 2) Assess the ability of chromosome 1 genes (q21-32) to predict disease phenotype [renal, cardiovascular, pulmonary, and central nervous system (CNS) involvement] in this profile cohort of SLE patients; and 3) Establish a core set of trio families (lupus patients and both biological parents) and healthy controls to confirm and narrow the identification of candidate regions and genes in SLE. The first two goals will be accomplished through a longitudinal study of 700 SLE patients. The third goal will be accomplished through a study on 350 trio families (lupus patients and both biological patients). There will be an additional cohort (called CASSLE) which will include 800 lupus patients with any disease duration, as well as 800 controls. Each control will be matched to a case by race, age, and gender. The procedures will be the same as in the PROFILE cohort, except that the participants will only have one study visit. These aims will serve to create the largest number of lupus patients in whom meticulously gathered data will be available to study the genetics of lupus and the relative contributions of genetics (versus other factors) to disease phenotype. The Chicago cohort aims to provide 300 PROFILE/CASSLE patients and 50 TRIO families as well as 200 matched Controls for lupus patients.